GenSight Biologics to Present at Upcoming Industry and Investor Conferences

Paris, France, September 20, 2022, 7:30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the Company will participate in the following industry and investor conferences:

The Business of Rare Policy Summit

September 20, 2022 – Washington DC, US

Bernard Gilly, Co-Founder & Chief Executive Officer, will take part in a panel discussion entitled “Business of Rare: State of the Industry” at 11:15 am EDT / 5:15 pm CEST.

GenSight Biologics is a headline sponsor of the conference and will also host a reception entitled “A Rare Pairing” at 4:30 pm EDT / 10:30 pm CEST.

Chardan’s 6^th Annual Genetic Medicines Conference

October 3 – 4, 2022 – New York, US Bernard Gilly, Co-Founder & Chief Executive Officer, and Thomas Gidoin, Chief Financial Officer, will attend in person on October 4, 2022, present in a fireside chat at 2.30 pm EDT / 8.30 pm CEST, and host investor meetings.

The fireside chat will be webcast live and in replay using this link.

4^th Annual HealthTech Innovation Days (HTID) 2022

October 13 – 14, 2022 – Paris, France & Virtual

Bernard Gilly, Co-Founder & Chief Executive Officer, and Thomas Gidoin, Chief Financial Officer, will attend in person and host investor meetings.

BTIG Ophthalmology Day 2022

November 29, 2022 – Virtual

Bernard Gilly, Co-Founder & Chief Executive Officer, and Thomas Gidoin, Chief Financial Officer, will participate and host investor meetings.